Sign In
Last checked at 
4 Mar 2020 15:28
ValiRx Plc
("ValiRx" or the "Company")
Shareholder Requisition Notice
London, UK, 4 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has received a letter from a group of shareholders (the "Letter") who hold in excess of 5% of the issued share capital of the Company, requiring that the Company convene, as soon as reasonably practicable, a general meeting, at which resolutions will be proposed to remove George Morris and Satu Vainikka as directors of the Company.
The Letter is a requisition under section 303 of the Companies Act 2006.
The Company is mindful that, pursuant to section 304 of the Companies Act 2006, the Company must post a notice convening a general meeting within 21 days from the date on which the requisition notice was received, and this general meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For more information, please contact:
ValiRx plc | Tel: +44 (0) 20 3008 4416 www.valirx.com |
Kevin Alexander, Non-executive Director | Tel: +44 (0) 20 3008 4416 |
Tarquin Edwards, Head of Communications. | Tel: +44 (0) 7879 458 364 tarquin.edwards@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
Allenby Capital Limited (Joint Broker) Jeremy Porter / Alex Brearley (Corporate Finance) Kelly Gardiner (Equity Sales) | Tel: +44 (0) 20 3328 5656
|
ETX Capital Limited (Joint Broker) Thomas Smith | Tel: +44 (0) 20 7392 1568
|
Novum Securities Limited (Joint Broker) Colin Rowbury | Tel: +44 (0) 20 7399 9400 |
Follow the stocks
